Insmed (NASDAQ:INSM) CEO Sells $3,247,335.00 in Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 19,215 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the sale, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. This represents a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Down 2.6%

Shares of Insmed stock opened at $159.27 on Friday. The firm has a market cap of $33.97 billion, a PE ratio of -25.73 and a beta of 1.08. The business’s 50 day simple moving average is $188.29 and its 200 day simple moving average is $153.54. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same period last year, the company earned ($1.27) EPS. The company’s revenue was up 52.4% compared to the same quarter last year. On average, analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in Insmed by 67.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 17,542 shares of the biopharmaceutical company’s stock worth $3,053,000 after buying an additional 7,076 shares during the last quarter. Private Advisory Group LLC bought a new position in shares of Insmed during the 4th quarter worth approximately $479,000. ORG Partners LLC increased its holdings in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 74 shares during the last quarter. CoreCap Advisors LLC acquired a new position in shares of Insmed during the 4th quarter worth approximately $27,000. Finally, E. Ohman J or Asset Management AB bought a new stake in Insmed in the 4th quarter valued at $912,000.

Analyst Ratings Changes

Several brokerages have issued reports on INSM. Wells Fargo & Company set a $195.00 price target on shares of Insmed in a research note on Thursday, December 18th. HC Wainwright decreased their price objective on Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a report on Thursday, December 18th. TD Cowen dropped their target price on Insmed from $269.00 to $241.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. The Goldman Sachs Group increased their price target on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Cantor Fitzgerald raised their price target on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average price target of $205.77.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.